Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) Short Interest Update

Posted by Anthony Miller on Mar 29th, 2026

Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR – Get Free Report) was the recipient of a significant decline in short interest in the month of March. As of March 13th, there was short interest totaling 622 shares, a decline of 43.3% from the February 26th total of 1,097 shares. Currently, 0.4% of the company’s shares are sold short. Based on an average daily volume of 1,322 shares, the days-to-cover ratio is currently 0.5 days.

Amplify Weight Loss Drug & Treatment ETF Stock Performance

Amplify Weight Loss Drug & Treatment ETF stock traded down $0.01 during midday trading on Friday, hitting $23.66. 115 shares of the company’s stock were exchanged, compared to its average volume of 2,631. Amplify Weight Loss Drug & Treatment ETF has a 12 month low of $18.56 and a 12 month high of $27.28. The company has a market cap of $3.55 million, a PE ratio of 24.31 and a beta of 0.61. The firm has a 50-day moving average of $25.48 and a two-hundred day moving average of $24.91.

Amplify Weight Loss Drug & Treatment ETF Announces Dividend

The business also recently announced an annual dividend, which was paid on Wednesday, December 31st. Shareholders of record on Tuesday, December 30th were given a dividend of $0.4132 per share. This represents a yield of 162.0%. The ex-dividend date of this dividend was Tuesday, December 30th.

Hedge Funds Weigh In On Amplify Weight Loss Drug & Treatment ETF

An institutional investor recently raised its position in Amplify Weight Loss Drug & Treatment ETF stock. Jane Street Group LLC lifted its position in Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR – Free Report) by 5.1% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 24,891 shares of the company’s stock after purchasing an additional 1,215 shares during the quarter. Jane Street Group LLC owned about 19.15% of Amplify Weight Loss Drug & Treatment ETF worth $536,000 as of its most recent SEC filing.

About Amplify Weight Loss Drug & Treatment ETF

(Get Free Report)

The Amplify Weight Loss Drug & Treatment ETF (THNR) is an exchange-traded fund that is based on the VettaFi Weight Loss Drug index. The fund tracks a modified market cap-weighted index of companies from developed markets that manufacture and enable GLP-1 agonist pharmaceutical businesses. THNR was launched on May 21, 2024 and is issued by Amplify Investments.